Literature DB >> 22349620

Intravenous immunoglobulin: exploiting the potential of natural antibodies.

Srini V Kaveri1.   

Abstract

Antibodies present in healthy conditions in the absence of deliberate immunization or infections are called natural antibodies. A significant proportion of natural antibody pool is believed to interact with self-antigens, and thus is called natural autoantibodies. Natural autoantibodies belong to IgG, IgM and IgA subclasses, and are encoded by V(D)J genes in germline configuration and bind to self molecules with varying affinities. In addition to serving in first line defense mechanism, natural antibodies participate in the homeostasis of the immune system. Intravenous immunoglobulin (IVIg) is a therapeutic preparation that contains substantial amount of natural antibodies exclusively of IgG subclass. In addition to its role in protection against pathogens in primary and secondary immunodeficiency patients, IVIg exerts a number of immunoregulatory functions through its interaction with innate and adaptive immune system and thereby imposing immune homeostasis.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22349620     DOI: 10.1016/j.autrev.2012.02.006

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  37 in total

1.  Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.

Authors:  Mohan S Maddur; Magalie Rabin; Pushpa Hegde; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Jagadeesh Bayry; Srini V Kaveri
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

2.  Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD.

Authors:  Scott E Counts; Debomoy K Lahiri
Journal:  Curr Alzheimer Res       Date:  2014       Impact factor: 3.498

Review 3.  Polyvalent immunoglobulins: challenges and perspectives.

Authors:  Isabella Quinti; Serelina Coluzzi; Federica Pulvirenti; Alessandro Prezzo; Gabriella Girelli
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

4.  Intravenous immunoglobulin for Alzheimer's disease.

Authors:  N Relkin
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 5.  Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future.

Authors:  Luca Cantarini; Donato Rigante; Antonio Vitale; Salvatore Napodano; Lazaros I Sakkas; Dimitrios P Bogdanos; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

6.  The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites.

Authors:  Christoph Schneider; David F Smith; Richard D Cummings; Kayluz Frias Boligan; Robert G Hamilton; Bruce S Bochner; Sylvia Miescher; Hans-Uwe Simon; Anastas Pashov; Tchavdar Vassilev; Stephan von Gunten
Journal:  Sci Transl Med       Date:  2015-01-07       Impact factor: 17.956

Review 7.  Clinical trials of intravenous immunoglobulin for Alzheimer's disease.

Authors:  Norman Relkin
Journal:  J Clin Immunol       Date:  2014-04-24       Impact factor: 8.317

Review 8.  Immunoglobulin-mediated neuro-cognitive impairment: new data and a comprehensive review.

Authors:  Assaf Menachem; Joab Chapman; Yael Deri; Chaim G Pick; Aviva Katzav
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

9.  FcμR in human B cell subsets in primary selective IgM deficiency, and regulation of FcμR and production of natural IgM antibodies by IGIV.

Authors:  Sudhir Gupta; Sudhanshu Agrawal; Sastry Gollapudi; Hiromi Kubagawa
Journal:  Hum Immunol       Date:  2016-10-14       Impact factor: 2.850

Review 10.  Chipping away at a mountain: genomic studies in common variable immunodeficiency.

Authors:  Michael D Keller; Soma Jyonouchi
Journal:  Autoimmun Rev       Date:  2012-11-29       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.